{
  "id": "crusade_bleeding_risk",
  "title": "CRUSADE Score for Post-MI Bleeding Risk",
  "description": "Risk stratifies patients with NSTEMI undergoing anticoagulation to determine their risk of major bleeding during hospitalization",
  "category": "cardiology",
  "version": "2010",
  "parameters": [
    {
      "name": "baseline_hematocrit",
      "type": "float",
      "required": true,
      "description": "Baseline hematocrit percentage on admission",
      "validation": {
        "min": 15.0,
        "max": 55.0
      },
      "unit": "percentage"
    },
    {
      "name": "creatinine_clearance",
      "type": "float",
      "required": true,
      "description": "Calculated creatinine clearance using Cockcroft-Gault equation",
      "validation": {
        "min": 5.0,
        "max": 200.0
      },
      "unit": "mL/min"
    },
    {
      "name": "heart_rate",
      "type": "integer",
      "required": true,
      "description": "Heart rate on admission in beats per minute",
      "validation": {
        "min": 30,
        "max": 200
      },
      "unit": "bpm"
    },
    {
      "name": "patient_sex",
      "type": "string",
      "required": true,
      "description": "Patient biological sex (female patients have higher bleeding risk)",
      "options": ["male", "female"],
      "validation": {
        "enum": ["male", "female"]
      },
      "unit": "sex"
    },
    {
      "name": "signs_chf",
      "type": "string",
      "required": true,
      "description": "Signs of congestive heart failure at presentation (dyspnea, rales, elevated JVP, S3 gallop)",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      },
      "unit": "presence"
    },
    {
      "name": "diabetes_mellitus",
      "type": "string",
      "required": true,
      "description": "History of diabetes mellitus (Type 1 or Type 2)",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      },
      "unit": "presence"
    },
    {
      "name": "prior_vascular_disease",
      "type": "string",
      "required": true,
      "description": "History of prior vascular disease (PAD, cerebrovascular disease, aortic aneurysm)",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      },
      "unit": "presence"
    },
    {
      "name": "systolic_blood_pressure",
      "type": "integer",
      "required": true,
      "description": "Systolic blood pressure on admission in mmHg",
      "validation": {
        "min": 60,
        "max": 250
      },
      "unit": "mmHg"
    }
  ],
  "result": {
    "name": "crusade_score",
    "type": "integer",
    "unit": "points",
    "description": "Total CRUSADE score ranging from 1-100 points predicting major bleeding risk"
  },
  "interpretation": {
    "ranges": [
      {
        "min": 1,
        "max": 20,
        "stage": "Very Low Risk",
        "description": "Very low bleeding risk",
        "interpretation": "CRUSADE score ≤20 indicates very low bleeding risk (3.1% major bleeding rate). Standard antithrombotic therapy is appropriate. Monitor for bleeding but expect low incidence."
      },
      {
        "min": 21,
        "max": 30,
        "stage": "Low Risk",
        "description": "Low bleeding risk",
        "interpretation": "CRUSADE score 21-30 indicates low bleeding risk (5.5% major bleeding rate). Standard antithrombotic therapy is appropriate with routine monitoring for bleeding complications."
      },
      {
        "min": 31,
        "max": 40,
        "stage": "Moderate Risk",
        "description": "Moderate bleeding risk",
        "interpretation": "CRUSADE score 31-40 indicates moderate bleeding risk (8.6% major bleeding rate). Consider reduced-dose antithrombotic therapy and enhanced bleeding monitoring. Balance ischemic vs bleeding risk."
      },
      {
        "min": 41,
        "max": 50,
        "stage": "High Risk",
        "description": "High bleeding risk",
        "interpretation": "CRUSADE score 41-50 indicates high bleeding risk (11.9% major bleeding rate). Consider reduced-dose antithrombotic regimens, shorter duration therapy, and intensive bleeding monitoring."
      },
      {
        "min": 51,
        "max": 100,
        "stage": "Very High Risk",
        "description": "Very high bleeding risk",
        "interpretation": "CRUSADE score >50 indicates very high bleeding risk (19.5% major bleeding rate). Strongly consider alternative treatment strategies, minimal effective antithrombotic therapy, and very close monitoring."
      }
    ]
  },
  "references": [
    "Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009;119(14):1873-1882.",
    "Abu-Assi E, Raposeiras-Roubin S, Lear P, et al. The risk of bleeding according to the CRUSADE, ACUITY and HAS-BLED scores in acute coronary syndrome patients treated with prasugrel: insights from a four-year registry. Thromb Res. 2013;132(6):652-658.",
    "Ariza-Solé A, Sánchez-Elvira G, Sánchez-Salado JC, et al. CRUSADE bleeding score validation for ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Thromb Res. 2013;132(6):652-658."
  ],
  "formula": "Sum of weighted points: Hematocrit + Creatinine Clearance + Heart Rate + Sex + CHF Signs + Diabetes + Vascular Disease + Systolic BP",
  "notes": [
    "Developed and validated in NSTEMI patients undergoing antithrombotic therapy",
    "Major bleeding defined as: hematocrit drop ≥12%, RBC transfusion (if baseline Hct ≥28%), or RBC transfusion with witnessed bleeding (if baseline Hct <28%)",
    "Score ranges from 1-100 points with higher scores indicating greater bleeding risk",
    "Validated in both NSTEMI and STEMI patients",
    "Should be used in conjunction with ischemic risk assessment for optimal decision-making",
    "Consider patient-specific factors and bleeding history not captured in the score",
    "Useful for selecting appropriate antithrombotic regimens and monitoring intensity",
    "Can guide duration of dual antiplatelet therapy",
    "Female sex independently associated with increased bleeding risk"
  ]
}